1,790 reports of this reaction
1.3% of all LEUPROLIDE ACETATE reports
#17 most reported adverse reaction
PROSTATE CANCER is the #17 most commonly reported adverse reaction for LEUPROLIDE ACETATE, manufactured by TOLMAR Inc.. There are 1,790 FDA adverse event reports linking LEUPROLIDE ACETATE to PROSTATE CANCER. This represents approximately 1.3% of all 133,873 adverse event reports for this drug.
Patients taking LEUPROLIDE ACETATE who experience prostate cancer should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PROSTATE CANCER is a less commonly reported adverse event for LEUPROLIDE ACETATE, but still significant enough to appear in the safety profile.
In addition to prostate cancer, the following adverse reactions have been reported for LEUPROLIDE ACETATE:
The following drugs have also been linked to prostate cancer in FDA adverse event reports:
PROSTATE CANCER has been reported as an adverse event in 1,790 FDA reports for LEUPROLIDE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PROSTATE CANCER accounts for approximately 1.3% of all adverse event reports for LEUPROLIDE ACETATE, making it a notable side effect.
If you experience prostate cancer while taking LEUPROLIDE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.